ENDP / Endo International plc - Pemfailan SEC, Laporan Tahunan, Penyata Proksi

ENDPQ / Endo International plc / Oaktree Capital Group Holdings GP, LLC - EXHIBIT 24.1

EX-24.1 2 ef20043591ex24-1.htm EXHIBIT 24.1 Exhibit 24.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned with respect to the Common Stock, par value $0.01 par value per share, of Endo International plc, and that all subsequent amendments to this statement on Schedule 13

PURCHASE AND SALE AGREEMENT by and among Endo Enterprise, Inc., Endo USA, Inc. and Paladin Pharma Inc. as the Buyers Endo International plc and the other Sellers (as defined herein), as the Sellers Dated as of April 14, 2024

Exhibit 2.1 EXECUTION VERSION PURCHASE AND SALE AGREEMENT by and among Endo Enterprise, Inc., Endo USA, Inc. and Paladin Pharma Inc. as the Buyers and Endo International plc and the other Sellers (as defined herein), as the Sellers Dated as of April 14, 2024 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS Section 1.1 Certain Defined Terms 2 Section 1.2 Table of Definitions 24 ARTICLE II PURCHASE AND

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 14, 2024 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 19, 2024 Endo International

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 19, 2024 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fi

FINDINGS OF FACT, CONCLUSIONS OF LAW, AND ORDER (I) CONFIRMING THE FOURTH AMENDED JOINT CHAPTER 11 PLAN OF REORGANIZATION OF ENDO INTERNATIONAL PLC AND ITS AFFILIATED DEBTORS AND (II) APPROVING THE DISCLOSURE STATEMENT WITH RESPECT THERETO

Exhibit 99.1 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK Chapter 11 In re Case No. 22-22549 (JLG) ENDO INTERNATIONAL plc, et al., (Jointly Administered) Debtors.1 Re: Docket Nos. 3554, 3849 FINDINGS OF FACT, CONCLUSIONS OF LAW, AND ORDER (I) CONFIRMING THE FOURTH AMENDED JOINT CHAPTER 11 PLAN OF REORGANIZATION OF ENDO INTERNATIONAL PLC AND ITS AFFILIATED DEBTORS AND (II) APPROVING

FOURTH AMENDED JOINT CHAPTER 11 PLAN OF REORGANIZATION OF ENDO INTERNATIONAL PLC AND ITS AFFILIATED DEBTORS

Exhibit 2.1 UNITED STATES BANKRUPTCY COURT  SOUTHERN DISTRICT OF NEW YORK In re Chapter 11 ENDO INTERNATIONAL plc, et al., Case No. 22-22549 (JLG) Debtors.1 (Jointly Administered) FOURTH AMENDED JOINT CHAPTER 11 PLAN OF REORGANIZATION OF ENDO INTERNATIONAL PLC AND ITS AFFILIATED DEBTORS Paul D. Leake Lisa Laukitis Shana A. Elberg Evan A. Hill SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP One Manhattan

Endo Announces Confirmation of Plan of Reorganization Anticipates Completing Financial Restructuring as Early as Late April 2024

EX-99.2 Exhibit 99.2 Endo Announces Confirmation of Plan of Reorganization Anticipates Completing Financial Restructuring as Early as Late April 2024 DUBLIN, March 19, 2024 — Endo International plc (OTC: ENDPQ) (“Endo” or the “Company”) today announced that the United States Bankruptcy Court for the Southern District of New York has confirmed its Chapter 11 plan of reorganization (the “Plan”), cle

Civil Settlement Agreement, dated February 20, 2024, among the United States, Endo Health Solutions Inc. and Loretta Reed

Exhibit 10.40 SETTLEMENT AGREEMENT This Settlement Agreement (this “Agreement”) is entered into among (a) the United States of America, acting through the United States Department of Justice and on behalf of the Office of Inspector General (OIG-HHS) of the Department of Health and Human Services (HHS), the Defense Health Agency (DHA), acting on behalf of the TRICARE Program; the Office of Personne

Plea Agreement, dated February 27, 2024, between the United States and Endo Health Solutions Inc.

Page 1 of 15 Exhibit 10.39 U.S. Department of Justice Consumer Protection Branch 450 5th St NW Washington, DC 20001 February 27, 2024 Sean M. Berkowitz, Esq. Garrett S. Long, Esq. Latham & Watkins LLP 330 North Wabash Avenue Suite 2800 Chicago, Illinois 60611 Carole S. Rendon, Esq. Sarah Spring, Esq. BakerHostetler LLP 127 Public Square, Suite 2000 Cleveland, Ohio 44114-1214 Re: Plea Agreement wit

ENDO REPORTS FOURTH-QUARTER 2023 FINANCIAL RESULTS

Exhibit 99.1 ENDO REPORTS FOURTH-QUARTER 2023 FINANCIAL RESULTS DUBLIN, March 6, 2024 - Endo International plc (OTC: ENDPQ) today reported financial results for the fourth-quarter ended December 31, 2023. FOURTH-QUARTER FINANCIAL PERFORMANCE (in thousands, except per share amounts) Three Months Ended December 31, Year Ended December 31, 2023 2022 Change 2023 2022 Change Total Revenues, Net $ 497,7

Global Settlement Agreement, dated February 28, 2024, by and among the United States of America, Endo Inc. and Endo International PLC

Exhibit 10.38 Execution Version SETTLEMENT AGREEMENT This SETTLEMENT AGREEMENT (“Agreement”), dated February 28, 2024, is entered into by and among (a) the United States of America, acting through the United States Attorney’s Office for the Southern District of New York, for and on behalf of (i) the United States Department of Justice Civil Division’s Consumer Protection Branch (“DOJ-CPB”); (ii) t

Subsidiaries of the Registrant

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT The following is a list of the subsidiaries of the Company as of December 31, 2023. Subsidiary Jurisdiction of Incorporation or Organization Ownership by Endo International plc 70 Maple Avenue, LLC Delaware Indirect Actient Pharmaceuticals LLC Delaware Indirect Actient Therapeutics, LLC Delaware Indirect Anchen Incorporated New York Indirect Anchen Pharm

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 6, 2024 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36326 Endo Internatio

Power of Attorney

Exhibit 24.1 POWER OF ATTORNEY Each of the undersigned, hereby constitutes and appoints each of Blaise Coleman, Mark T. Bradley, Matthew J. Maletta and Brian Morrissey to be his or her true and lawful attorneys-in-fact and agents, with full power of each to act alone, and to sign for the undersigned and in each of their respective names in any and all capacities stated below, this Annual Report on

Notice of Filing of Second Amended and Restated Restructuring Support Agreement

Exhibit 10.1 SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP Paul D. Leake Lisa Laukitis Shana A. Elberg Evan A. Hill One Manhattan West New York, New York 10001 Telephone: (212) 735-3000 Fax: (212) 735-2000 Counsel for Debtors and Debtors in Possession UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF NEW YORK In re Chapter 11 ENDO INTERNATIONAL plc, et al., Case No. 22-22549 (JLG) Debtors.1 (Jointly

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 28, 2023 Endo Internatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 28, 2023 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 28, 2023 Endo Internatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 28, 2023 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission

ENDO FILES PLAN OF REORGANIZATION TO IMPLEMENT PREVIOUSLY ANNOUNCED SALE TRANSACTION Paves the Way for Endo to Successfully Conclude Financial Restructuring in Second Quarter of 2024

Exhibit 99.1 ENDO FILES PLAN OF REORGANIZATION TO IMPLEMENT PREVIOUSLY ANNOUNCED SALE TRANSACTION Paves the Way for Endo to Successfully Conclude Financial Restructuring in Second Quarter of 2024 DUBLIN, December 19, 2023 – Endo International plc (OTC: ENDPQ) (“Endo” or the “Company”) today announced that it has taken an important step toward concluding its financial restructuring process by filin

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 19, 2023 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 28, 2023 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission

Regulation FD Disclosure, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 6, 2023 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission

ENDO REPORTS THIRD-QUARTER 2023 FINANCIAL RESULTS

Exhibit 99.1 ENDO REPORTS THIRD-QUARTER 2023 FINANCIAL RESULTS DUBLIN, November 6, 2023 — Endo International plc (OTC: ENDPQ) today reported financial results for the third-quarter ended September 30, 2023. THIRD-QUARTER FINANCIAL PERFORMANCE (in thousands, except per share amounts) Three Months Ended September 30, Nine Months Ended September 30, 2023 2022 Change 2023 2022 Change Total Revenues, N

Disclaimer This document has been prepared by Endo International plc (“Endo” or the “Company”) and its advisors from information provided by Company management and other sources, and is subject in all respects to the confidentiality agreement you hav

Long Term Plan Update November 6, 2023 Cleansing Material Preliminary and Subject to Material Change Exhibit 99.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-36326 Endo

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 29, 2023 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commissio

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 7, 2023 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 29, 2023 Endo Internationa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 29, 2023 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission F

THIS DOCUMENT AND THE ACCOMPANYING FORM OF PROXY ARE IMPORTANT AND REQUIRE YOUR IMMEDIATE ATTENTION.

Exhibit 99.1 THIS DOCUMENT AND THE ACCOMPANYING FORM OF PROXY ARE IMPORTANT AND REQUIRE YOUR IMMEDIATE ATTENTION. If you sold or otherwise transferred all of your ordinary shares of nominal value $0.0001 each in the capital of Endo International plc (Ordinary Shares) prior to the Record Date, you should forward this document to the purchaser or transferee or to the stockbroker, bank or other agent

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 15, 2023 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 ☐ TRANSITION REPORT PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-36326 Endo Inter

ENDO REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTS

Exhibit 99.1 ENDO REPORTS SECOND-QUARTER 2023 FINANCIAL RESULTS DUBLIN, August 8, 2023 - Endo International plc (OTC: ENDPQ) today reported financial results for the second-quarter ended June 30, 2023. SECOND-QUARTER FINANCIAL PERFORMANCE (in thousands, except per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2023 2022 Change 2023 2022 Change Total Revenues, Net $ 546,852 $

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 8, 2023 Endo International

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 8, 2023 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 28, 2023 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 26, 2023 Endo International p

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 26, 2023 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 8, 2023 Endo International pl

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 8, 2023 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission File

ENDO REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTS

Exhibit 99.1 ENDO REPORTS FIRST-QUARTER 2023 FINANCIAL RESULTS DUBLIN, May 8, 2023 - Endo International plc (OTC: ENDPQ) today reported financial results for the first-quarter ended March 31, 2023. FIRST-QUARTER FINANCIAL PERFORMANCE (in thousands, except per share amounts) Three Months Ended March 31, 2023 2022 Change Total Revenues, Net $ 515,267 $ 652,259 (21) % Reported Loss from Continuing Op

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 ☐ TRANSITION REPORT P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-36326 Endo Inte

Executive Employment Agreement between Endo Health Solutions Inc. and James Tursi, dated December 15, 2021 and effective January 18, 2022

Exhibit 10.1 ENDO HEALTH SOLUTIONS INC. EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT (this “Agreement”) is hereby entered into as of December 15, 2021, by and between Endo Health Solutions Inc. (the “Company”), a wholly-owned subsidiary of Endo International plc (“Endo”), and James Tursi (“Executive”) (hereinafter collectively referred to as “the parties”). In consideration of the respective agre

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRAN

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-3

Retention Agreement between Endo and James Tursi, dated July 11, 2022

Exhibit 10.2 Personal and Confidential July 11, 2022 c/o Endo International plc First Floor, Minerva House, Simmonscourt Road Ballsbridge, Dublin, Ireland Re: 2022 Retention Program Dear James: As previously disclosed, Endo International plc (“Endo” or the “Company”) is focused on exploring strategic alternatives that it believes are in the best interests of the Company. While we cannot speculate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 29, 2023 Endo International

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 29, 2023 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 3, 2023 Endo International

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 3, 2023 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 6, 2023 Endo International

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 6, 2023 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fil

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36326 Endo Internatio

Subsidiaries of the Registrant

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT The following is a list of the subsidiaries of the Company as of December 31, 2022. Subsidiary Jurisdiction of Incorporation or Organization Ownership by Endo International plc 70 Maple Avenue, LLC Delaware Indirect Actient Pharmaceuticals LLC Delaware Indirect Actient Therapeutics, LLC Delaware Indirect Anchen Incorporated New York Indirect Anchen Pharm

Power of Attorney

Exhibit 24.1 POWER OF ATTORNEY Each of the undersigned, hereby constitutes and appoints each of Blaise Coleman, Mark T. Bradley, Matthew J. Maletta and Brian Morrissey to be his or her true and lawful attorneys-in-fact and agents, with full power of each to act alone, and to sign for the undersigned and in each of their respective names in any and all capacities stated below, this Annual Report on

ENDO REPORTS FOURTH-QUARTER 2022 FINANCIAL RESULTS

Exhibit 99.1 ENDO REPORTS FOURTH-QUARTER 2022 FINANCIAL RESULTS DUBLIN, March 6, 2023 - Endo International plc (OTC: ENDPQ) today reported financial results for the fourth-quarter ended December 31, 2022. FOURTH-QUARTER FINANCIAL PERFORMANCE (in thousands, except per share amounts) Three Months Ended December 31, Year Ended December 31, 2022 2021 Change 2022 2021 Change Total Revenues, Net $ 555,8

As filed with the Securities and Exchange Commission on February 27, 2023

S-8 POS As filed with the Securities and Exchange Commission on February 27, 2023 Registration Statement No.

As filed with the Securities and Exchange Commission on February 27, 2023

S-8 POS As filed with the Securities and Exchange Commission on February 27, 2023 Registration Statement No.

As filed with the Securities and Exchange Commission on February 27, 2023

S-8 POS As filed with the Securities and Exchange Commission on February 27, 2023 Registration Statement No.

As filed with the Securities and Exchange Commission on February 27, 2023

S-8 POS As filed with the Securities and Exchange Commission on February 27, 2023 Registration Statement No.

As filed with the Securities and Exchange Commission on February 27, 2023

S-8 POS As filed with the Securities and Exchange Commission on February 27, 2023 Registration Statement No.

As filed with the Securities and Exchange Commission on February 27, 2023

S-8 POS As filed with the Securities and Exchange Commission on February 27, 2023 Registration Statement No.

As filed with the Securities and Exchange Commission on February 27, 2023

POSASR As filed with the Securities and Exchange Commission on February 27, 2023 Registration No.

Table of Contents 2022A Unaudited Results Feb 2023 Long Term Plan Feb 2023 Segment Projections

EX-99.1 Long Term Plan Update February 13, 2023 Cleansing Material Preliminary and Subject to Material Change Exhibit 99.1 Table of Contents 2022A Unaudited Results Feb 2023 Long Term Plan Feb 2023 Segment Projections 2022A results exceeded expectations 2022A vs July LBE Highlights 2022A total revenue exceeded expectations primarily driven by Varenicline (delayed competition), partially offset by

1

EX-99.2 Exhibit 99.2 SUPPLEMENTAL FINANCIAL INFORMATION Non-GAAP Financial Measures The Company utilizes certain financial measures that are not prescribed by or prepared in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP financial measures are not, and should not be viewed as, substitutes for GAAP net income and its components and diluted net income per

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 6, 2023 Endo Internation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 6, 2023 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13

15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36326 ENDO INTERNATIONAL PLC (Exact name of registrant as specifi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 23, 2023 Endo Internation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 23, 2023 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 29, 2022 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 21, 2022 Endo Internatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 21, 2022 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission

Disclaimer This document has been prepared by Endo International plc (“Endo” or the “Company”) and its advisors from information provided by Company management and other sources, and is subject in all respects to the confidentiality agreement you hav

EX-99.1 Exhibit 99.1 Nevakar Litigation Update December 20, 2022 Confidential Cleansing Material Subject to FRE 408 & State Law Equivalents Preliminary and Subject to Material Change endo.com Disclaimer This document has been prepared by Endo International plc (“Endo” or the “Company”) and its advisors from information provided by Company management and other sources, and is subject in all respect

Endo to Cease Production and Sale of Qwo® (collagenase clostridium histolyticum-aaes)

EX-99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Endo to Cease Production and Sale of Qwo® (collagenase clostridium histolyticum-aaes) DUBLIN, December 6, 2022 – Endo International plc (OTC: ENDPQ) announced today that it will cease the production and sale of Endo Aesthetics’ Qwo® (collagenase clostridium histolyticum-aaes) in light of market concerns about the extent and variability of bruising followi

Disclaimer This document has been prepared by Endo International plc (“Endo” or the “Company”) and its advisors from information provided by Company management and other sources and is subject in all respects to the confidentiality agreement you have

EX-99.2 Exhibit 99.2 Qwo Update December 2022 Confidential Cleansing Material endo.com Disclaimer This document has been prepared by Endo International plc (“Endo” or the “Company”) and its advisors from information provided by Company management and other sources and is subject in all respects to the confidentiality agreement you have executed with the Company. All communications or inquiries rel

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 6, 2022 Endo Internation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 6, 2022 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 30, 2022 Endo Internatio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 30, 2022 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission

Amendment, dated as of August 13, 2022, to Executive Employment Agreement between Endo Health Solutions Inc. and Mark T. Bradley, effective March 6, 2020

Exhibit 10.8 Personal and Confidential August 13, 2022 c/o Endo International plc First Floor, Minerva House, Simmonscourt Road Ballsbridge, Dublin, Ireland Re: Employment Agreement Extension Dear Mark: In connection with the accelerated payment of your 2023 incentive compensation, Endo International plc (?Endo? or the ?Company?) wishes to amend your employment agreement with the Company, dated as

Retention Agreement between Endo and Matthew J. Maletta, dated August 11, 2022

Exhibit 10.4 Personal and Confidential August 11, 2022 c/o Endo International plc First Floor, Minerva House, Simmonscourt Road Ballsbridge, Dublin, Ireland Re: 2022 Retention Program Dear Matthew: As previously disclosed, Endo International plc (?Endo? or the ?Company?) is focused on exploring strategic alternatives that it believes are in the best interests of the Company. While we cannot specul

Retention Agreement between Endo and Patrick Barry, dated August 11, 2022

Exhibit 10.5 Personal and Confidential August 11, 2022 c/o Endo International plc First Floor, Minerva House, Simmonscourt Road Ballsbridge, Dublin, Ireland Re: 2022 Retention Program Dear Patrick: As previously disclosed, Endo International plc (?Endo? or the ?Company?) is focused on exploring strategic alternatives that it believes are in the best interests of the Company. While we cannot specul

Amendment, dated as of August 13, 2022, to Executive Employment Agreement between Endo Health Solutions Inc. and Blaise Coleman, effective March 6, 2020

Exhibit 10.6 Personal and Confidential August 13, 2022 c/o Endo International plc First Floor, Minerva House, Simmonscourt Road Ballsbridge, Dublin, Ireland Re: Employment Agreement Extension Dear Blaise: In connection with the accelerated payment of your 2023 incentive compensation, Endo International plc (?Endo? or the ?Company?) wishes to amend your employment agreement with the Company, dated

Amendment, dated as of August 13, 2022, to Executive Employment Agreement between Endo Health Solutions Inc. and Matthew Maletta, effective February 13, 2021

Exhibit 10.9 Personal and Confidential August 13, 2022 c/o Endo International plc First Floor, Minerva House, Simmonscourt Road Ballsbridge, Dublin, Ireland Re: Employment Agreement Extension Dear Matthew: In connection with the accelerated payment of your 2023 incentive compensation, Endo International plc (?Endo? or the ?Company?) wishes to amend your employment agreement with the Company, dated

Amendment, dated as of August 13, 2022, to Executive Employment Agreement between Endo Health Solutions Inc. and Patrick Barry, effective April 26, 2020

Exhibit 10.7 Personal and Confidential August 13, 2022 c/o Endo International plc First Floor, Minerva House, Simmonscourt Road Ballsbridge, Dublin, Ireland Re: Employment Agreement Extension Dear Patrick: In connection with the accelerated payment of your 2023 incentive compensation, Endo International plc (?Endo? or the ?Company?) wishes to amend your employment agreement with the Company, dated

ENDO REPORTS THIRD-QUARTER 2022 FINANCIAL RESULTS

Exhibit 99.1 ENDO REPORTS THIRD-QUARTER 2022 FINANCIAL RESULTS DUBLIN, November 9, 2022 - Endo International plc (OTC: ENDPQ) today reported financial results for the third-quarter ended September 30, 2022. THIRD-QUARTER FINANCIAL PERFORMANCE (in thousands, except per share amounts) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 Change 2022 2021 Change Total Revenues, N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-36326 Endo

Retention Agreement between Endo and Mark T. Bradley, dated August 11, 2022

Exhibit 10.3 Personal and Confidential August 11, 2022 c/o Endo International plc First Floor, Minerva House, Simmonscourt Road Ballsbridge, Dublin, Ireland Re: 2022 Retention Program Dear Mark: As previously disclosed, Endo International plc (?Endo? or the ?Company?) is focused on exploring strategic alternatives that it believes are in the best interests of the Company. While we cannot speculate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2022 Endo Internation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 9, 2022 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission

Retention Agreement between Endo and Blaise Coleman, dated August 11, 2022

Exhibit 10.2 Personal and Confidential August 11, 2022 c/o Endo International plc First Floor, Minerva House, Simmonscourt Road Ballsbridge, Dublin, Ireland Re: 2022 Retention Program Dear Blaise: As previously disclosed, Endo International plc (?Endo? or the ?Company?) is focused on exploring strategic alternatives that it believes are in the best interests of the Company. While we cannot specula

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 17, 2022 Endo Internation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 17, 2022 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 6, 2022 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission F

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 26, 2022 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commissio

ENDP / Endo International PLC / MILLENNIUM MANAGEMENT LLC Passive Investment

SC 13G 1 ENDPAug2022SC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ENDO INTERNATIONAL PLC (Name of Issuer) ORDINARY SHARES, NOMINAL VALUE $0.0001 PER SHARE (Title of Class of Securities) G30401106 (CUSIP Number) AUGUST 17, 2022 (Date of event which requires filing of this statement) Check the appropriate box

Endo International plc (Incorporated in Ireland with limited liability under the Companies Act 2014 with registered number 534814) Notice of Extraordinary General Meeting Convened Pursuant to Section 1111 of the Companies Act 2014

Exhibit 99.1 If you sell or have sold or otherwise transferred all of your ordinary shares of $0.0001 each in the capital of Endo International plc (?Ordinary Shares?) you should forward this document to the purchaser or transferee or to the stockbroker, bank or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee. If you have sold or otherwise

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 26, 2022 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission F

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 16, 2022 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission F

Restructuring Support Agreement, dated August 16, 2022, by and among the Debtors and the members of the Ad Hoc First Lien Group

Exhibit 10.1 EXECUTION VERSION RESTRUCTURING SUPPORT AGREEMENT This RESTRUCTURING SUPPORT AGREEMENT (as amended, modified, or otherwise supplemented from time to time, this ?Agreement?), dated as of August 16, 2022, is entered into by and among: (a) Endo International plc (?Parent?) and each of its undersigned subsidiaries (each, including Parent, a ?Debtor,? and collectively, the ?Debtors?); and

Endo Enters Into Restructuring Support Agreement with Senior Secured Debtholders to Strengthen Financial Position and Advance Ongoing Business Transformation Sale Transaction Would Result in a Substantial Reduction of Debt and Contemplates Purchaser-

Exhibit 99.1 Endo Enters Into Restructuring Support Agreement with Senior Secured Debtholders to Strengthen Financial Position and Advance Ongoing Business Transformation Sale Transaction Would Result in a Substantial Reduction of Debt and Contemplates Purchaser-Established Voluntary Trusts Funded with $550 Million to Benefit Opioid Claimants Patients and Customers Will Continue to Receive Highest

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Bankruptcy or Receivership

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 11, 2022 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission F

Management Presentation June 2022 Confidential Subject to Confidentiality Agreement Cleansing Material Subject to FRE 408 & State Law Equivalents Preliminary and Subject to Material Change endo.com

Exhibit 99.2 Management Presentation June 2022 Confidential Subject to Confidentiality Agreement Cleansing Material Subject to FRE 408 & State Law Equivalents Preliminary and Subject to Material Change endo.com Disclaimer This document has been prepared by Endo International plc (?Endo? or the ?Company?) and its advisors from information provided by Company management and other sources, and is sub

ENDO REPORTS SECOND-QUARTER 2022 FINANCIAL RESULTS

Exhibit 99.1 ENDO REPORTS SECOND-QUARTER 2022 FINANCIAL RESULTS DUBLIN, August 9, 2022 - Endo International plc (NASDAQ: ENDP) today reported financial results for the second-quarter ended June 30, 2022. SECOND-QUARTER FINANCIAL PERFORMANCE (in thousands, except per share amounts) Three Months Ended June 30, Six Months Ended June 30, 2022 2021 Change 2022 2021 Change Total Revenues, Net $ 569,114

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2022 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 ☐ TRANSITION REPORT PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-36326 Endo Inter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 28, 2022 Endo International

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 28, 2022 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fil

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 15, 2022 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fil

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 1, 2022 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission File

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 30, 2022 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fil

ENDP / Endo International PLC / MILLENNIUM MANAGEMENT LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ENDO INTERNATIONAL PLC (Name of Issuer) ORDINARY SHARES, NOMINAL VALUE $0.0001 PER SHARE (Title of Class of Securities) G30401106 (CUSIP Number) JUNE 17, 2022 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant t

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 9, 2022 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission File

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 ☐ TRANSITION REPORT P

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-36326 Endo Inte

ENDO REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS

Exhibit 99.1 ENDO REPORTS FIRST-QUARTER 2022 FINANCIAL RESULTS DUBLIN, May 5, 2022 - Endo International plc (NASDAQ: ENDP) today reported financial results for the first-quarter ended March 31, 2022 and provided second-quarter 2022 financial guidance. ?Despite challenging market dynamics for VASOSTRICT?, our first-quarter financial performance was in-line with our expectations with growth in our B

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 5, 2022 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission File

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 2, 2022 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission File

Endo Acquires Six Development-Stage, Ready-to-Use Injectable Product Candidates From Nevakar

Exhibit 99.1 Endo Acquires Six Development-Stage, Ready-to-Use Injectable Product Candidates From Nevakar DUBLIN, May 2, 2022 ? Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) acquired six development-stage, ready-to-use injectable product candidates from Nevakar Injectables Inc., a subsidiary of Nevakar, Inc. ?These six product candidates that

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 29, 2022 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registran

DEF 14A 1 d46171ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registran

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

Retention Agreement between Endo and Blaise Coleman, dated November 1, 2021

Exhibit 10.22 Personal and Confidential November 1, 2021 c/o Endo International plc First Floor, Minerva House, Simmonscourt Road Ballsbridge, Dublin, Ireland Re: 2021 Retention Program Dear Blaise: As previously disclosed, Endo International plc (?Endo? or the ?Company?) is focused on its primary goal of achieving a global settlement of all remaining opioid claims. At the same time, Endo is explo

Retention Agreement between Endo and Patrick Barry, dated November 1, 2021

Exhibit 10.25 Personal and Confidential November 1, 2021 c/o Endo International plc First Floor, Minerva House, Simmonscourt Road Ballsbridge, Dublin, Ireland Re: 2021 Retention Program Dear Patrick: As previously disclosed, Endo International plc (?Endo? or the ?Company?) is focused on its primary goal of achieving a global settlement of all remaining opioid claims. At the same time, Endo is expl

Description of Registrant’s Securities

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of our annual report on Form 10-K of which this exhibit is a part, we have the following class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): ordinary shares of Endo International plc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36326 Endo Internatio

Retention Agreement between Endo and Mark T. Bradley, dated November 1, 2021

Exhibit 10.23 Personal and Confidential November 1, 2021 c/o Endo International plc First Floor, Minerva House, Simmonscourt Road Ballsbridge, Dublin, Ireland Re: 2021 Retention Program Dear Mark: As previously disclosed, Endo International plc (?Endo? or the ?Company?) is focused on its primary goal of achieving a global settlement of all remaining opioid claims. At the same time, Endo is explori

Subsidiaries of the Registrant

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT The following is a list of the subsidiaries of the Company as of December 31, 2021. Subsidiary Jurisdiction of Incorporation or Organization Ownership by Endo International plc 70 Maple Avenue, LLC Delaware Indirect Actient Pharmaceuticals LLC Delaware Indirect Actient Therapeutics, LLC Delaware Indirect Anchen Incorporated New York Indirect Anchen Pharm

Power of Attorney

Exhibit 24.1 POWER OF ATTORNEY Each of the undersigned, hereby constitutes and appoints each of Blaise Coleman, Mark T. Bradley, Matthew J. Maletta and Brian Morrissey to be his or her true and lawful attorneys-in-fact and agents, with full power of each to act alone, and to sign for the undersigned and in each of their respective names in any and all capacities stated below, this Annual Report on

Retention Agreement between Endo and Matthew J. Maletta, dated November 1, 2021

Exhibit 10.24 Personal and Confidential November 1, 2021 c/o Endo International plc First Floor, Minerva House, Simmonscourt Road Ballsbridge, Dublin, Ireland Re: 2021 Retention Program Dear Matthew: As previously disclosed, Endo International plc (?Endo? or the ?Company?) is focused on its primary goal of achieving a global settlement of all remaining opioid claims. At the same time, Endo is expl

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 28, 2022 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission

ENDO REPORTS FOURTH-QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS

Exhibit 99.1 ENDO REPORTS FOURTH-QUARTER AND FULL-YEAR 2021 FINANCIAL RESULTS DUBLIN, February 28, 2022 - Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth-quarter and full-year ended December 31, 2021 and introduced first-quarter 2022 financial guidance. "Endo?s solid operational and financial performance in the fourth-quarter ended a year of strong performance

ENDP / Endo International PLC / PAULSON & CO. INC. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Endo International plc (Name of Issuer) Ordinary Shares, $0.0001 nominal value per share (Title of Class of Securities) G30401106 (CUSIP Nu

ENDP / Endo International PLC / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Endo International plc Title of Class of Securities: Common Stock CUSIP Number: G30401106 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed

©2022 Endo International plc or one of its affiliates. All rights reservedendo.com J.P. Morgan Healthcare Conference Blaise Coleman, President & CEO ©2022 Endo International plc or one of its affiliates. All rights reserved This presentation contains

jpmdeckxfinal ©2022 Endo International plc or one of its affiliates. All rights reservedendo.com J.P. Morgan Healthcare Conference Blaise Coleman, President & CEO ©2022 Endo International plc or one of its affiliates. All rights reserved This presentation contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1 995 and Canadian securities legislat

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 11, 2022 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 ☐ TRANSITION REPO

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-36326 Endo

ENDO REPORTS THIRD-QUARTER 2021 FINANCIAL RESULTS AND RAISES 2021 FINANCIAL GUIDANCE

EX-99.1 2 a20210930ex991earningsrele.htm EX-99.1 Exhibit 99.1 ENDO REPORTS THIRD-QUARTER 2021 FINANCIAL RESULTS AND RAISES 2021 FINANCIAL GUIDANCE DUBLIN, November 4, 2021 - Endo International plc (NASDAQ: ENDP) today reported financial results for the third-quarter ended September 30, 2021. "We delivered strong third-quarter results driven by outstanding execution across all of our businesses. As

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 4, 2021 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 29, 2021 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission

As filed with the Securities and Exchange Commission on August 6, 2021

Table of Contents As filed with the Securities and Exchange Commission on August 6, 2021 Registration No.

Form T-1 of Statement of Eligibility under the Trust Indenture Act of 1939 of Wells Fargo Bank, National Association, as trustee under the Debt Securities Indenture.

EX-25.1 5 d603209dex251.htm EX-25.1 Exhibit 25.1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ☐ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b) (2) WELLS FARGO BANK, NATIONAL ASSOCIATION (Exact name of trustee as s

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 ☐ TRANSITION REPORT PU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-36326 Endo Inter

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 5, 2021 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fi

ENDO REPORTS SECOND-QUARTER 2021 FINANCIAL RESULTS AND UPDATES 2021 FINANCIAL GUIDANCE

Exhibit 99.1 ENDO REPORTS SECOND-QUARTER 2021 FINANCIAL RESULTS AND UPDATES 2021 FINANCIAL GUIDANCE DUBLIN, August 5, 2021 - Endo International plc (NASDAQ: ENDP) today reported financial results for the second-quarter ended June 30, 2021. "Our second-quarter 2021 results reflect strong sequential growth in our Branded Pharmaceuticals segment driven by XIAFLEX?, and better than expected performanc

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 10, 2021 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fil

Form of Performance Award Agreement under the Endo International plc Amended and Restated 2015 Stock Incentive Plan

Exhibit 10.3 ENDO INTERNATIONAL PLC PERFORMANCE AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2015 STOCK INCENTIVE PLAN This Performance Award Agreement, which shall include the TSR Performance Award Grant Notice, the FCF Performance Award Grant Notice and the Terms and Conditions (collectively, the ?Award Agreement?) is made and entered into as of [ ] by and between Endo International plc, an Ir

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-36326 Endo Inte

Form of Long-Term Cash Award Agreement under the Endo International plc Amended and Restated 2015 Stock Incentive Plan

Exhibit 10.4 Grant No. ENDO INTERNATIONAL PLC LONG-TERM CASH AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2015 STOCK INCENTIVE PLAN This Award Agreement (this ?Award Agreement?), is made and entered into as of the date of grant set forth below (the ?Date of Grant?) by and between Endo International plc, an Irish public limited company (the ?Company?), and the participant named below (the ?Partic

Cash Continuity Arrangement between Endo and George Apostol, dated November 5, 2020

Exhibit 10.6 November 5, 2020 George Apostol First Floor, Minverva House Ballsbridge, D4 Ireland Dear George, Your exceptional leadership and business expertise are critical to Endo (?Endo? or the ?Company?) as we continue to advance our mission to develop and deliver life-enhancing products through focused execution. You are one of Endo?s key leaders who is critical to the implementation of our s

Form of Stock Award Agreement under the Endo International plc Amended and Restated 2015 Stock Incentive Plan

Exhibit 10.2 Grant No. ENDO INTERNATIONAL PLC STOCK AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2015 STOCK INCENTIVE PLAN This Stock Award Agreement (this ?Award Agreement?), is made and entered into as of the date of grant set forth below (the ?Date of Grant?) by and between Endo International plc, an Irish public limited company (the ?Company?), and the participant named below (the ?Participa

ENDO REPORTS FIRST-QUARTER 2021 FINANCIAL RESULTS AND UPDATES 2021 FINANCIAL GUIDANCE

EX-99.1 2 a20210331ex991earningsrele.htm EX-99.1 Exhibit 99.1 ENDO REPORTS FIRST-QUARTER 2021 FINANCIAL RESULTS AND UPDATES 2021 FINANCIAL GUIDANCE DUBLIN, May 6, 2021 - Endo International plc (NASDAQ: ENDP) today reported financial results for the first-quarter ended March 31, 2021. "I am proud of the continued strong execution across each of Endo’s business segments as reflected by our better th

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 6, 2021 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission File

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 29, 2021 Endo International plc (Exact name of registrant as specified in its charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fi

Executive Employment Agreement between Endo Ventures Limited and George Apostol, effective April 29, 2021

EX-10.1 2 a20210429ex101apostolemplo.htm EX-10.1 Exhibit 10.1 Execution Version ENDO VENTURES LIMITED EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT (this “Agreement”) is hereby entered into as of April 29, 2021 (the “Effective Date”), by and between (i) Endo Ventures Limited (the “Company”) (registered number 534474) of First Floor, Minerva House, Simmonscourt Road, Ballsbridge, Dublin 4, Ireland,

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)). ? Defi

Schedule 14A

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) ? Filed by the Registrant ? Filed by a Party other than the Registrant Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 25, 2021 Endo International plc (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fi

Amendment and Restatement Agreement, dated as of March 25, 2021, by and among Endo International plc, Endo Luxembourg Finance Company I S.à r.l., Endo LLC, the lenders and other parties party thereto and JPMorgan Chase Bank, N.A. as administrative agent, issuing bank and swingline lender, which amends and restates the Credit Agreement, dated as of April 27, 2017

EX-10.1 3 d120772dex101.htm EX-10.1 Exhibit 10.1 Execution Version AMENDMENT AND RESTATEMENT AGREEMENT THIS AMENDMENT AND RESTATEMENT AGREEMENT, dated as of March 25, 2021 (this “Restatement Agreement”), is by and among Endo International PLC, a company incorporated in the Republic of Ireland (Registered Number 534814) (“Parent”), Endo Luxembourg Finance Company I S.à r.l., a société à responsabil

Indenture, dated as of March 25, 2021, among Endo Luxembourg Finance Company I S.à r.l., Endo U.S. Inc., the guarantors named therein and Wells Fargo Bank, National Association, as trustee, relating to the 6.125% Senior Secured Notes due 2029 (including Form of 6.125% Senior Secured Notes due 2029)

Exhibit 4.1 Execution Version March 25, 2021 Endo Luxembourg Finance Company I S.? r.l. and Endo U.S. Inc. (as Issuers) and Each of the Guarantors Party hereto and Wells Fargo Bank, National Association (as Trustee) INDENTURE 6.125% Senior Secured Notes due 2029 TABLE OF CONTENTS Page ARTICLE 1. DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01 Definitions 1 Section 1.02 Other Definitions 49

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 11, 2021 Endo International plc (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fi

Endo International plc Announces Pricing of Private Offering Of Senior Secured Notes

EX-99.1 Exhibit 99.1 Endo International plc Announces Pricing of Private Offering Of Senior Secured Notes DUBLIN, March 11, 2021 – Endo International plc (NASDAQ: ENDP) (“Endo”) today announced that its wholly-owned subsidiaries Endo Luxembourg Finance Company I S.à r.l. (“Endo Luxembourg”) and Endo U.S. Inc. (together with Endo Luxembourg, the “Issuers”) priced $1.295 billion aggregate principal

Endo International plc Announces Proposed Private Offering Of Senior Secured Notes

EX-99.1 2 d153342dex991.htm EX-99.1 Exhibit 99.1 Endo International plc Announces Proposed Private Offering Of Senior Secured Notes DUBLIN, March 11, 2021 – Endo International plc (NASDAQ: ENDP) (“Endo”) today announced that its wholly-owned subsidiaries Endo Luxembourg Finance Company I S.à r.l. (“Endo Luxembourg”) and Endo U.S. Inc. (together with Endo Luxembourg, the “Issuers”) intend to offer

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 11, 2021 Endo International plc (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fi

Endo International plc Commences Refinancing of its Existing Term Loan

Exhibit 99.1 Endo International plc Commences Refinancing of its Existing Term Loan DUBLIN, March 4, 2021 ? Endo International plc (NASDAQ: ENDP) (?Endo?) today announced that it has commenced a refinancing of its existing $3.3 billion senior secured term loan due 2024 with the net proceeds of a new senior secured term loan and other debt issuances. The new term loan will have the same guarantees

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 4, 2021 Endo International plc (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fil

Cash Continuity Arrangement between Endo and Matthew J. Maletta, dated November 5, 2020

Exhibit 10.35 November 5, 2020 Matthew Maletta 1400 Atwater Drive Malvern, PA 19355 Dear Matthew, Your exceptional leadership and business expertise are critical to Endo (?Endo? or the ?Company?) as we continue to advance our mission to develop and deliver life-enhancing products through focused execution. You are one of Endo?s key leaders who is critical to the implementation of our strategy and

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36326 Endo Internatio

Description of Registrant’s Securities

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of our annual report on Form 10-K of which this exhibit is a part, we have the following class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?): ordinary shares of Endo International plc

Power of Attorney

Exhibit 24.1 POWER OF ATTORNEY Each of the undersigned, hereby constitutes and appoints each of Blaise Coleman, Mark Bradley, Matthew J. Maletta and Brian Morrissey to be his or her true and lawful attorneys-in-fact and agents, with full power of each to act alone, and to sign for the undersigned and in each of their respective names in any and all capacities stated below, this Annual Report on Fo

Separation Agreement and General Release between Endo and Terrance J. Coughlin, dated November 19, 2020

Exhibit 10.24 SEPARATION AGREEMENT & GENERAL RELEASE This Separation Agreement and General Release, dated November 19, 2020 (this ?Agreement?) is entered into by and between Terrance J. Coughlin (?Executive?) and Endo Health Solutions, Inc. (the ?Company?) (together with Executive, the ?Parties?), a wholly-owned subsidiary of Endo International plc (?Endo?). Capitalized terms not defined herein sh

Cash Continuity Arrangement between Endo and Mark Bradley, dated November 5, 2020

Exhibit 10.34 November 5, 2020 Mark Bradley 1400 Atwater Drive Malvern, PA 19355 Dear Mark, Your exceptional leadership and business expertise are critical to Endo (?Endo? or the ?Company?) as we continue to advance our mission to develop and deliver life-enhancing products through focused execution. You are one of Endo?s key leaders who is critical to the implementation of our strategy and the pu

Cash Continuity Arrangement between Endo and Patrick Barry, dated November 5, 2020

Exhibit 10.33 November 5, 2020 Patrick Barry 1400 Atwater Drive Malvern, PA 19355 Dear Patrick, Your exceptional leadership and business expertise are critical to Endo (?Endo? or the ?Company?) as we continue to advance our mission to develop and deliver life-enhancing products through focused execution. You are one of Endo?s key leaders who is critical to the implementation of our strategy and th

Subsidiaries of the Registrant

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT The following is a list of the subsidiaries of the Company as of December 31, 2020. Subsidiary Jurisdiction of Incorporation or Organization Ownership by Endo International plc 70 Maple Avenue, LLC Delaware Indirect Actient Pharmaceuticals LLC Delaware Indirect Actient Therapeutics, LLC Delaware Indirect Anchen Incorporated New York Indirect Anchen Pharm

Cash Continuity Arrangement between Endo and Blaise Coleman, dated November 5, 2020

Exhibit 10.32 November 5, 2020 Blaise Coleman 1400 Atwater Drive Malvern, PA 19355 Dear Blaise, Your exceptional leadership and business expertise are critical to Endo (?Endo? or the ?Company?) as we continue to advance our mission to develop and deliver life-enhancing products through focused execution. You are one of Endo?s key leaders who is critical to the implementation of our strategy and th

ENDO REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 FINANCIAL RESULTS AND INTRODUCES 2021 FINANCIAL GUIDANCE

Exhibit 99.1 ENDO REPORTS FOURTH-QUARTER AND FULL-YEAR 2020 FINANCIAL RESULTS AND INTRODUCES 2021 FINANCIAL GUIDANCE DUBLIN, February 25, 2021 - Endo International plc (NASDAQ: ENDP) today reported financial results for the fourth-quarter and full-year ended December 31, 2020 and introduced 2021 financial guidance. ?I am proud of all that the Endo team achieved in a very challenging year. We made

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 25, 2021 Endo International plc (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 17, 2021 Endo International plc (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission

Endo Appoints Jennifer M. Chao to Board of Directors

EX-99.1 2 a20200217ex991chaopressrel.htm EX-99.1 Exhibit 99.1 Endo Appoints Jennifer M. Chao to Board of Directors DUBLIN, February 17, 2021 - Endo International plc (NASDAQ: ENDP) today announced that its Board of Directors has appointed Jennifer M. Chao to serve as a director, effective immediately. Ms. Chao has also been appointed to Endo’s Audit Committee and its Compliance Committee and becom

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ENDO INTERNATIONAL PLC (Name of Issuer) Ordinary Shares, $0.0001 par value per share (Title of Class of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ENDO INTERNATIONAL PLC (Name of Issuer) Ordinary Shares, $0.0001 par value per share (Title of Class of Securities) G30401106 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Endo International plc (Name of Issuer) Common Stock (Title of Class of Securities) G30401106 (CUSIP Num

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Endo International plc (Name of Issuer) Common Stock (Title of Class of Securities) G30401106 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Endo International plc (Name of Issuer) Ordinary Shares, $0.0001 nominal value per share (Title of Class of Securities) G30401106 (CUSIP Nu

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Endo International plc Title of Class of Securities: Common Stock CUSIP Number: G30401106 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed

©2021 Endo International plc or one of its affiliates. All rights reservedendo.com J.P. Morgan Healthcare Conference Blaise Coleman, President & CEO ©2021 Endo International plc or one of its affiliates. All rights reserved This presentation contains

jpmdeckxfinal ©2021 Endo International plc or one of its affiliates. All rights reservedendo.com J.P. Morgan Healthcare Conference Blaise Coleman, President & CEO ©2021 Endo International plc or one of its affiliates. All rights reserved This presentation contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1 995 and Canadian securities legislat

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 12, 2021 Endo International plc (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission

BSTC / BioSpecifics Technologies Corp. / Endo International plc - SC 13D/A Activist Investment

SC 13D/A 1 d40475dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) BIOSPECIFICS TECHNOLOGIES CORP. (Name of Issuer) Common Stock, par value $0.001 per share (Title of C

Endo Completes Acquisition of BioSpecifics

EX-99.1 2 d67240dex991.htm EX-99.1 Exhibit 99.1 Endo Completes Acquisition of BioSpecifics DUBLIN, December 2, 2020 – Endo International plc (NASDAQ: ENDP) announced today that it completed the previously announced acquisition of BioSpecifics Technologies Corp., a commercial-stage biopharmaceutical company, for $88.50 per share in an all-cash transaction, for an estimated enterprise value of appro

- SC TO-T/A (AMENDMENT NO. 3)

SC TO-T/A 1 d65516dsctota.htm SC TO-T/A (AMENDMENT NO. 3) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 3) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BIOSPECIFICS TECHNOLOGIES CORP. (Name of Subject Company) BETA ACQUISITION CORP. (Offeror) A Wholly-Owned Subsidiary of ENDO INTERNATIONA

Press Release, dated December 2, 2020, announcing the expiration and results of the Offer and the consummation of the Merger.*

EX-99.a.5.D Exhibit (a)(5)(D) Endo Completes Acquisition of BioSpecifics DUBLIN, December 2, 2020 – Endo International plc (NASDAQ: ENDP) announced today that it completed the previously announced acquisition of BioSpecifics Technologies Corp., a commercial-stage biopharmaceutical company, for $88.50 per share in an all-cash transaction, for an estimated enterprise value of approximately $540 mill

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 2, 2020 Endo International plc (Exact name of registrant as specified in charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission File

- SC TO-T/A (AMENDMENT NO. 2)

SC TO-T/A (Amendment No. 2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 2) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BIOSPECIFICS TECHNOLOGIES CORP. (Name of Subject Company) BETA ACQUISITION CORP. (Offeror) A Wholly-Owned Subsidiary of ENDO INTERNATIONAL PLC (Parent of Offeror) (Nam

Press Release issued by Endo, dated November 18, 2020, announcing expiration of the waiting period under the HSR Act.*

EX-99.A.5.C 2 d32198dex99a5c.htm EX-99.A.5.C Exhibit (a)(5)(C) ENDO ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD FOR BIOSPECIFICS TENDER OFFER DUBLIN — November 18, 2020 — Endo International plc (Nasdaq: ENDP) (“Endo”) today announced the expiration of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection w

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-36326 Endo

- SC TO-T/A

SC TO-T/A 1 d13988dsctota.htm SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 1) Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BIOSPECIFICS TECHNOLOGIES CORP. (Name of Subject Company) BETA ACQUISITION CORP. (Offeror) A Wholly-Owned Subsidiary of ENDO INTERNATIONAL PLC (Parent of O

Executive Employment Agreement between Endo Health Solutions Inc. and Matthew Maletta, effective February 13, 2021

EX-10.2 2 ex102-malettaemploymen.htm EX-10.2 Exhibit 10.2 ENDO HEALTH SOLUTIONS INC. EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT (this "Agreement") is hereby entered into as of November 4, 2020, effective as of February 13, 2021 (the “Effective Date”), by and between Endo Health Solutions Inc. (the "Company"), a wholly-owned subsidiary of Endo International plc ("Endo"), and Matthew J. Maletta (

ENDO REPORTS THIRD-QUARTER 2020 FINANCIAL RESULTS AND RAISES FULL YEAR 2020 FINANCIAL GUIDANCE

Exhibit 99.1 ENDO REPORTS THIRD-QUARTER 2020 FINANCIAL RESULTS AND RAISES FULL YEAR 2020 FINANCIAL GUIDANCE DUBLIN, November 5, 2020 - Endo International plc (NASDAQ: ENDP) today reported financial results for the third-quarter ended September 30, 2020. "Our third-quarter 2020 results reflect growth in our Branded Pharmaceuticals segment as utilization of physician administered products continues

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 5, 2020 Endo International plc (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission

Form of Letter of Transmittal (including Internal Revenue Service Form W-9).*

Exhibit (a)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of BIOSPECIFICS TECHNOLOGIES CORP.

Form of Notice of Guaranteed Delivery.*

Exhibit (a)(1)(C) Exhibit (a)(1)(C) NOTICE OF GUARANTEED DELIVERY For Tender of Shares of Common Stock of BIOSPECIFICS TECHNOLOGIES CORP.

Summary Newspaper Advertisement, as published in The Wall Street Journal on November 2, 2020.*

Exhibit (a)(1)(F) Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below).

Press Release, dated November 2, 2020, announcing commencement of the Offer.*

Exhibit (a)(5)(B) Exhibit (a)(5)(B) ENDO INTERNATIONAL PLC COMMENCES TENDER OFFER FOR ALL OUTSTANDING SHARES OF BIOSPECIFICS TECHNOLOGIES CORP.

Form of Letter to Brokers, Dealers, Banks, Trust Companies and Other Nominees.*

Exhibit (a)(1)(D) Exhibit (a)(1)(D) Offer To Purchase For Cash All Outstanding Shares of Common Stock of BIOSPECIFICS TECHNOLOGIES CORP.

Offer to Purchase, dated as of November 2, 2020.*

Exhibit (a)(1)(A) Table of Contents Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock of BioSpecifics Technologies Corp.

- SC TO-T

SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BIOSPECIFICS TECHNOLOGIES CORP. (Name of Subject Company) BETA ACQUISITION CORP. (Offeror) A Wholly-Owned Subsidiary of ENDO INTERNATIONAL PLC (Parent of Offeror) (Names of Filing Persons (identifying stat

Form of Letter to Clients for use by Brokers, Dealers, Banks, Trust Companies and Other Nominees.*

Exhibit (a)(1)(E) Exhibit (a)(1)(E) Offer To Purchase For Cash All Outstanding Shares of Common Stock of BIOSPECIFICS TECHNOLOGIES CORP.

Confidentiality Agreement, dated as of September 22, 2020, between Endo International plc and BioSpecifics Technologies Corp.*

Exhibit (d)(3) Exhibit (d)(3) BioSpecifics Technologies Corp. 2 Righter Parkway Delaware Corporate Center II Wilmington, DE 19803 September 22, 2020 Matthew J. Maletta Executive Vice President, Chief Legal Officer and Company Secretary Endo International plc 1400 Atwater Drive Malvern PA 19355 Dear Blaise: In connection with Endo International plc’s (“Endo,” “you” or “your”) interest in a potentia

BioSpecifics Technologies Corp. 2 Righter Parkway Delaware Corporate Center II Wilmington, DE 19803

EXHIBIT 4 Exhibit 4 BioSpecifics Technologies Corp. 2 Righter Parkway Delaware Corporate Center II Wilmington, DE 19803 September 22, 2020 Matthew J. Maletta Executive Vice President, Chief Legal Officer and Company Secretary Endo International plc 1400 Atwater Drive Malvern PA 19355 Dear Blaise: In connection with Endo International plc’s (“Endo,” “you” or “your”) interest in a potential acquisit

BSTC / BioSpecifics Technologies Corp. / Endo International plc - SC 13D Activist Investment

SC 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) BIOSPECIFICS TECHNOLOGIES CORP. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 090931106 (CUSIP Number) Matthe

JOINT FILING AGREEMENT

EX-99.3 2 d45739dex993.htm EXHIBIT 3 EXHIBIT 3 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.001 per share, of BioSpecifics Technologies Corp., and fu

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 19, 2020 Endo International plc (Exact Name of Registrant as Specified in Charter) Ireland 001-36326 68-0683755 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

- SC TO-C

SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 BIOSPECIFICS TECHNOLOGIES CORP. (Name of Subject Company (Issuer)) BETA ACQUISITION CORP. a wholly owned subsidiary of ENDO INTERNATIONAL PLC (Name of Filing Persons (Offerors)) Common Stock, $0.001 Par Value (T

- SC TO-C

SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): October 19, 2020 Endo International plc (Exact Name of Registrant as Specified in Charter) Ireland 001-36326 68-0683755 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.

Social media post made on October 19, 2020

EX-(a)(5)(B) Exhibit (a)(5)(B) BREAKING: Endo has reached an agreement to acquire BioSpecifics Technologies Corp.

Email to Parent employees, dated October 19, 2020, from the Chief Executive Officer

EX-99.(A)(5)(A) 2 d75114dex99a5a.htm EX-(A)(5)(A) Exhibit (a)(5)(A) TO: All Employees SUBJECT: Important Company Announcement: Endo to Acquire BioSpecifics Technologies Corp. Team members, I’m excited to share with you that Endo has reached an agreement to acquire BioSpecifics Technologies Corp. (NASDAQ: BSTC), a commercial-stage biopharmaceutical company. Under the terms of the agreement, Endo wi

Agreement and Plan of Merger, dated as of October 19, 2020, by and among BioSpecifics Technologies Corp., Endo International plc, and Beta Acquisition Corp.

EX-2.1 2 d87354dex21.htm EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG ENDO INTERNATIONAL PLC, BETA ACQUISITION CORP. AND BIOSPECIFICS TECHNOLOGIES CORP. DATED AS OF OCTOBER 19, 2020 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS & INTERPRETATIONS 2 1.1 Certain Definitions 2 1.2 Cross-References 14 1.3 Certain Interpretations 17 ARTICLE II THE OFFER 18 2.1 The Offer 18 2.2 Company Act

Support Agreement, dated as of October 19, 2020, by and among Endo International plc, Beta Acquisition Corp and the Marital Trust U/W/O Edwin H. Wegman dated 8-10-06.

EX-10.1 Exhibit 10.1 SUPPORT AGREEMENT This SUPPORT AGREEMENT, dated as of October 19, 2020 (this “Agreement”), is made and entered into by and among Endo International plc, a public limited company incorporated in Ireland (“Parent”), Beta Acquisition Corp., a Delaware corporation and a wholly-owned subsidiary of Parent (“Merger Sub”), and the Marital Trust U/W/O Edwin H. Wegman dated 8-10-06 (the

Endo to Acquire BioSpecifics to Enhance Profitability of XIAFLEX® and Qwo™ – Endo to acquire BioSpecifics in an accretive all-cash transaction –

EX-99.1 Exhibit 99.1 Endo to Acquire BioSpecifics to Enhance Profitability of XIAFLEX® and Qwo™ – Endo to acquire BioSpecifics in an accretive all-cash transaction – DUBLIN, October 19, 2020 –Endo International plc (NASDAQ: ENDP) today announced it has agreed to acquire all of the outstanding shares of BioSpecifics Technologies Corp. (NASDAQ: BSTC), a commercial-stage biopharmaceutical company, fo

EX-24

EX-24 2 smithpoa.htm SMITH POA LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS Know all by these present that the undersigned hereby makes, constitutes and appoints Matthew J. Maletta, John D. Boyle, Justin Dailey and Michael Baranowski as the undersigned's true and lawful attorneys-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place a

ENDO INTERNATIONAL PLC ANNOUNCES THE EXPIRATION AND FINAL TENDER RESULTS OF ITS PREVIOUSLY ANNOUNCED TENDER OFFER

EX-99.1 2 d29767dex991.htm EX-99.1 Exhibit 99.1 ENDO INTERNATIONAL PLC ANNOUNCES THE EXPIRATION AND FINAL TENDER RESULTS OF ITS PREVIOUSLY ANNOUNCED TENDER OFFER DUBLIN, August 21, 2020 — Endo International plc (the “Company”) (NASDAQ: ENDP) announced today the expiration and final tender results of the previously announced cash tender offer (the “Offer”) by its wholly owned subsidiary Endo Financ

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 21, 2020 Endo International plc (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission F

Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 17, 2020 Endo International plc (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission F

ENDO INTERNATIONAL PLC COMMENCES TENDER OFFER FOR ANY AND ALL OF ITS OUTSTANDING 5.75% SENIOR NOTES DUE 2022

EX-99.1 Exhibit 99.1 ENDO INTERNATIONAL PLC COMMENCES TENDER OFFER FOR ANY AND ALL OF ITS OUTSTANDING 5.75% SENIOR NOTES DUE 2022 DUBLIN, August 17, 2020 /PRNewswire/ - Endo International plc (the “Company” or “Endo”) (NASDAQ: ENDP) announced today that Endo Finance LLC (“Endo Finance”), a wholly-owned subsidiary of the Company, has commenced a cash tender offer for any and all of its outstanding

- S-8

S-8 As Filed with the Securities and Exchange Commission on August 6, 2020 Registration Statement No.

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-36326 Endo Inter

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 5, 2020 Endo International plc (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fi

ENDO REPORTS SECOND-QUARTER 2020 FINANCIAL RESULTS — Revenues decreased 2% to $688 million compared to prior year — — On July 6, 2020, U.S. FDA approved Qwo™ (collagenase clostridium histolyticum-aaes), the first injectable treatment for cellulite —

EX-99.1 2 a20200630ex991earnings.htm EX-99.1 PRESS RELEASE Exhibit 99.1 ENDO REPORTS SECOND-QUARTER 2020 FINANCIAL RESULTS — Revenues decreased 2% to $688 million compared to prior year — — On July 6, 2020, U.S. FDA approved Qwo™ (collagenase clostridium histolyticum-aaes), the first injectable treatment for cellulite — DUBLIN, August 5, 2020 - Endo International plc (NASDAQ: ENDP) today reported

Endo Appoints M. Christine Smith, Ph.D. to Board of Directors

Exhibit 99.1 Endo Appoints M. Christine Smith, Ph.D. to Board of Directors DUBLIN, July 29, 2020 - Endo International plc (NASDAQ: ENDP) today announced that its Board of Directors has appointed Christie Smith, Ph.D. to serve as a non-executive director, effective July 29, 2020. Most recently, Dr. Smith served as the Global Vice President for Inclusion and Diversity at Apple. Dr. Smith has also be

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 29, 2020 Endo International plc (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fil

Supplemental Indenture, dated as of May 28, 2020, among Endo Designated Activity Company, Endo Finance LLC, Endo Finco Inc., the guarantors named therein and Wells Fargo Bank, National Association, as trustee, to the Indenture, dated as of January 27, 2015, among Endo Designated Activity Company, Endo Finance LLC, Endo Finco Inc., the guarantors named therein and Wells Fargo Bank, National Association, as trustee, relating to the 6.000% Senior Notes due 2025

EX-4.9 Exhibit 4.9 Execution Version SUPPLEMENTAL INDENTURE SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of May 28, 2020, among Endo Designated Activity Company (formerly known as Endo Limited), a designated activity company incorporated under the laws of Ireland (the “Company”), Endo Finance LLC (formerly known as Endo Finance Co.), a Delaware limited liability company (“Endo

Second Lien Collateral Trust Agreement, dated as of June 16, 2020, by and among Endo International plc, certain subsidiaries of Endo International plc as borrowers, Endo Designated Activity Company, Endo Finance LLC, Endo Finco Inc., certain other grantors party thereto, JPMorgan Chase Bank, N.A, as administrative agent, Wells Fargo Bank, National Association, as trustee, and Wilmington Trust, National Association, as collateral trustee

EX-10.2 Exhibit 10.2 EXECUTION VERSION SECOND LIEN COLLATERAL TRUST AGREEMENT dated as of June 16, 2020 among ENDO INTERNATIONAL PLC, ENDO DESIGNATED ACTIVITY COMPANY, ENDO FINANCE LLC, ENDO FINCO INC., the other Grantors from time to time party hereto, WELLS FARGO BANK, NATIONAL ASSOCIATION, as Indenture Trustee, and WILMINGTON TRUST, NATIONAL ASSOCIATION, as Collateral Trustee TABLE OF CONTENTS

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 15, 2020 Endo International plc (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fil

Supplemental Indenture, dated as of May 28, 2020, among Endo Designated Activity Company, Endo Finance LLC, Endo Finco Inc., the guarantors named therein and Wells Fargo Bank, National Association, as trustee, to the Indenture, dated as of July 9, 2015, among Endo Designated Activity Company, Endo Finance LLC, Endo Finco Inc., the guarantors named therein and Wells Fargo Bank, National Association, as trustee, relating to the 6.000% Senior Notes due 2023

EX-4.8 Exhibit 4.8 Execution Version SUPPLEMENTAL INDENTURE SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of May 28, 2020, among Endo Designated Activity Company (formerly known as Endo Limited), a designated activity company incorporated under the laws of Ireland (the “Company”), Endo Finance LLC (formerly known as Endo Finance Co.), a Delaware limited liability company (“Endo

Intercreditor Agreement, dated as of June 16, 2020, by and among Wilmington Trust, National Association, as first priority representative, Wilmington Trust, National Association, as second priority representative, and certain grantors party thereto

EX-10.3 Exhibit 10.3 INTERCREDITOR AGREEMENT Intercreditor Agreement (this “Agreement”), dated as of June 16, 2020, among WILMINGTON TRUST, NATIONAL ASSOCIATION, as collateral trustee for the First Priority Secured Parties (as defined below) (in such capacity, with its successors and assigns, and as more specifically defined below, the “First Priority Representative”), WILMINGTON TRUST, NATIONAL A

Indenture, dated as of June 16, 2020, among Endo Designated Activity Company, Endo Finance LLC, Endo Finco Inc., the guarantors named therein and Wells Fargo Bank, National Association, as trustee, relating to the 9.500% Senior Secured Second Lien Notes due 2027 (including Form of 9.500% Senior Secured Second Lien Notes due 2027)

EX-4.4 Exhibit 4.4 Execution Version June 16, 2020 Endo Designated Activity Company, Endo Finance LLC and Endo Finco Inc. (as Issuers) and Each of the Guarantors Party hereto and Wells Fargo Bank, National Association (as Trustee) INDENTURE 9.500% Senior Secured Second Lien Notes due 2027 TABLE OF CONTENTS Page ARTICLE 1. DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01 Definitions 1 Sectio

First Supplemental Indenture, dated as of June 16, 2020, among Par Pharmaceutical, Inc., the guarantors named therein and Wells Fargo Bank, National Association, as trustee, to the Indenture, dated as of March 28, 2019, among Par Pharmaceutical, Inc., the guarantors named therein and Wells Fargo Bank, National Association, as trustee, relating to the 7.500% Senior Secured Notes due 2027

EX-4.2 Exhibit 4.2 Execution Version FIRST SUPPLEMENTAL INDENTURE Dated as of June 16, 2020 Among Par Pharmaceutical, Inc. as the Issuer, the Guarantors party hereto and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Trustee 7.500% SENIOR SECURED NOTES DUE 2027 This SUPPLEMENTAL INDENTURE, dated as of June 16, 2020 (this “Supplemental Indenture”), among Par Pharmaceutical, Inc., a New York corporation

Collateral Trust Agreement, dated as of April 27, 2017, by and among Endo International plc, certain subsidiaries of Endo International plc as borrowers, Par Pharmaceutical, Inc., certain other grantors party thereto, JPMorgan Chase Bank, N.A, as administrative agent, Wells Fargo Bank, National Association, as trustee, and Wilmington Trust, National Association, as collateral trustee

EX-10.1 Exhibit 10.1 Execution Version COLLATERAL TRUST AGREEMENT dated as of April 27, 2017 among ENDO INTERNATIONAL PLC, ENDO LUXEMBOURG FINANCE COMPANY I S.À R.L., ENDO LLC, ENDO DESIGNATED ACTIVITY COMPANY, ENDO FINANCE LLC, ENDO FINCO INC., the other Grantors from time to time party hereto, JPMORGAN CHASE BANK, N.A., as Administrative Agent under the Credit Agreement, and WELLS FARGO BANK, NA

Indenture, dated as of June 16, 2020, among Endo Designated Activity Company, Endo Finance LLC, Endo Finco Inc., the guarantors named therein and Wells Fargo Bank, National Association, as trustee, relating to the 6.000% Senior Notes due 2028 (including Form of 6.000% Senior Notes due 2028)

EX-4.6 4 d941026dex46.htm EX-4.6 Exhibit 4.6 Execution Version June 16, 2020 Endo Designated Activity Company, Endo Finance LLC and Endo Finco Inc. (as Issuers) and Each of the Guarantors Party hereto and Wells Fargo Bank, National Association (as Trustee) INDENTURE 6.000% Senior Notes due 2028 TABLE OF CONTENTS Page ARTICLE 1. DEFINITIONS AND INCORPORATION BY REFERENCE Section 1.01 Definitions 1

ENDO INTERNATIONAL PLC ANNOUNCES FINAL TENDER RESULTS OF ITS PREVIOUSLY ANNOUNCED EXCHANGE OFFERS AND CONSENT SOLICITATIONS

EX-99.1 10 d941026dex991.htm EX-99.1 Exhibit 99.1 ENDO INTERNATIONAL PLC ANNOUNCES FINAL TENDER RESULTS OF ITS PREVIOUSLY ANNOUNCED EXCHANGE OFFERS AND CONSENT SOLICITATIONS DUBLIN, June 15, 2020 /PRNewswire/ — MORE THAN 97% OF NOTES SOUGHT WERE TENDERED AND ACCEPTED THEREBY EXTENDING MORE THAN $2.7 BILLION OF ENDO INTERNATIONAL PLC’S NEAR-TERM DEBT MATURITIES REQUISITE CONSENTS OBTAINED PROVIDING

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 11, 2020 Endo International plc (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fil

Endo International plc Amended and Restated 2015 Stock Incentive Plan

Exhibit 10.1 ENDO INTERNATIONAL PLC AMENDED AND RESTATED 2015 STOCK INCENTIVE PLAN 1. Establishment and Purpose. The purpose of the Endo International plc Amended and Restated 2015 Stock Incentive Plan, as amended and restated June 11, 2020 (the “Plan”), is to promote the interests of the Company and the shareholders of the Company by providing directors, officers, employees and consultants of the

- DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) x Filed by the Registrant ¨ Filed by a Party other than the Registrant Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)). ¨ Defi

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 1, 2020 Endo International plc (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission File

ENDO INTERNATIONAL PLC ANNOUNCES EARLY TENDER RESULTS OF ITS PREVIOUSLY ANNOUNCED EXCHANGE OFFERS AND CONSENT SOLICITATIONS ENDO INTERNATIONAL PLC RECEIVES REQUISITE CONSENTS FOR 6.000% SENIOR NOTES DUE 2023 AND 6.000% SENIOR NOTES DUE 2025

EX-99.1 Exhibit 99.1 ENDO INTERNATIONAL PLC ANNOUNCES EARLY TENDER RESULTS OF ITS PREVIOUSLY ANNOUNCED EXCHANGE OFFERS AND CONSENT SOLICITATIONS ENDO INTERNATIONAL PLC RECEIVES REQUISITE CONSENTS FOR 6.000% SENIOR NOTES DUE 2023 AND 6.000% SENIOR NOTES DUE 2025 DUBLIN, May 29, 2020 /PRNewswire/ – Endo International plc (the “Company”) (NASDAQ: ENDP) announced today the early tender results of the

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 29, 2020 Endo International plc (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission File

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 28, 2020 Endo International plc (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission File

Endo International plc Announces Proposed Exchange Offers and Consent Solicitations

EX-99.1 Exhibit 99.1 Endo International plc Announces Proposed Exchange Offers and Consent Solicitations DUBLIN, May 14, 2020/PRNewswire/ – Endo International plc (the “Company”) (NASDAQ:ENDP) announced today that its wholly owned subsidiaries, Par Pharmaceutical, Inc., a New York corporation (“PPI”), Endo Designated Activity Company, a designated activity company incorporated under the laws of Ir

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 14, 2020 Endo International plc (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission File

Form of Performance Award Agreement under the Endo International plc Amended and Restated 2015 Stock Incentive Plan

Exhibit 10.1 ENDO INTERNATIONAL PLC PERFORMANCE AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2015 STOCK INCENTIVE PLAN This Performance Award Agreement, which shall include the TSR Performance Award Grant Notice, the FCF Performance Award Grant Notice and the Terms and Conditions (collectively, the “Award Agreement”) is made and entered into as of [ ] by and between Endo International plc, an Ir

Executive Employment Agreement between Endo Health Solutions Inc. and Patrick Barry, effective April 26, 2020

Exhibit 10.3 ENDO HEALTH SOLUTIONS INC. EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT (this “Agreement”) is hereby entered into as of April 28, 2020, effective as of April 26, 2020 (the “Effective Date”), by and between Endo Health Solutions Inc. (the “Company”), a wholly-owned subsidiary of Endo International plc (“Endo”), and Patrick Barry (“Executive”) (hereinafter collectively referred to as “

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2020 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-36326 Endo Intern

ENDO REPORTS FIRST-QUARTER 2020 FINANCIAL RESULTS AND PROVIDES UPDATE RELATING TO COVID-19 PANDEMIC — First quarter revenues increased 14% to $820 million versus prior year, augmented by approximately $75 million due to impact of coronavirus (COVID-1

Exhibit 99.1 ENDO REPORTS FIRST-QUARTER 2020 FINANCIAL RESULTS AND PROVIDES UPDATE RELATING TO COVID-19 PANDEMIC — First quarter revenues increased 14% to $820 million versus prior year, augmented by approximately $75 million due to impact of coronavirus (COVID-19) pandemic — — Full-year 2020 financial guidance withdrawn due to uncertainty regarding the continued impact of the COVID-19 pandemic —

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 7, 2020 Endo International plc (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission File

Cash Contribution Bonus Agreement between Endo and Patrick Barry, dated August 1, 2019

Exhibit 10.4 Endo 1400 Atwater Drive Malvern, PA 19355 484.216.0000 endo.com August 1, 2019 Patrick Barry 1400 Atwater Drive Malvern, Pennsylvania, 19355 Dear Pat, As we continue to execute on our corporate strategy, your leadership and expertise is essential to the Company. With the progress made to date, we are positioning ourselves for continued growth in Branded Pharmaceuticals and U.S. Brande

Form of Long-Term Cash Award Agreement under the Endo International plc Amended and Restated 2015 Stock Incentive Plan

Exhibit 10.2 Grant No. ENDO INTERNATIONAL PLC LONG-TERM CASH AWARD AGREEMENT UNDER THE AMENDED AND RESTATED 2015 STOCK INCENTIVE PLAN This Award Agreement (this “Award Agreement”), is made and entered into as of the date of grant set forth below (the “Date of Grant”) by and between Endo International plc, an Irish public limited company (the “Company”), and the participant named below (the “Partic

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 28, 2020 Endo International plc (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission Fi

- DEFA14A

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(A) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) ☒ Filed by the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

April 28, 2020

DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.

Executive Employment Agreement between Endo Health Solutions Inc. and Blaise Coleman, dated February 19, 2020 and effective March 6, 2020

Exhibit 10.18.1 EXECUTION VERSION ENDO HEALTH SOLUTIONS INC. EXECUTIVE EMPLOYMENT AGREEMENT THIS AGREEMENT (this “Agreement”) is hereby entered into as of February 19, 2020, effective as of March 6, 2020 (the “Effective Date”), by and between Endo Health Solutions Inc. (the “Company”), a wholly-owned subsidiary of Endo International plc (“Endo”), and Blaise Coleman (“Executive”) (hereinafter colle

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36326 Endo Internationa

Letter Agreement between Endo and Mark Bradley, dated May 17, 2018

Exhibit 10.24 Endo 1400 Atwater Drive Malvern, PA 19355 484.216.0000 endo.com May 17, 2018 Mark Bradley 9 Dillon Court Exton, PA 19341 Dear Mark: Based upon your outstanding achievements in 2017 and the criticality of your ongoing contributions to the planning and execution of Endo's ("Endo" or the "Company") transformation and turnaround, I am pleased to provide you with a special employment arra

Description of Registrant’s Securities

Exhibit 4.1 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of our annual report on Form 10-K of which this exhibit is a part, we have the following class of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): ordinary shares of Endo International plc

ENDO REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS — Strong Operational Performance Led by Year-over-Year Double-Digit-Percentage Revenue Growth in Sterile Injectables Segment and in Specialty Products Portfolio of Branded Pharmaceutica

Exhibit 99.1 ENDO REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS — Strong Operational Performance Led by Year-over-Year Double-Digit-Percentage Revenue Growth in Sterile Injectables Segment and in Specialty Products Portfolio of Branded Pharmaceuticals Segment — — Full-Year 2020 Financial Guidance Provided for Revenue, Adjusted Diluted Net Income per Share from Continuing Operations a

Cash Contribution Bonus Agreement between Endo and Mark Bradley, dated August 1, 2019

EX-10.23 5 ex1023mbcashcontributi.htm MB CASH CONTRIBUTION AGREEMENT Exhibit 10.23 Endo 1400 Atwater Drive Malvern, PA 19355 484.216.0000 endo.com August 1, 2019 Mark Bradley 9 Dillon Court Exton, Pennsylvania, 19341 Dear Mark, As we continue to execute on our corporate strategy, your leadership and expertise is essential to the Company. With the progress made to date, we are positioning ourselves

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 26, 2020 Endo International plc (Exact Name of Registrant as Specified in Its Charter) Ireland 001-36326 68-0683755 (State or other jurisdiction of incorporation) (Commission

Subsidiaries of the Registrant

Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT The following is a list of significant subsidiaries of the Company as of December 31, 2019. Subsidiary Jurisdiction of Incorporation or Organization Ownership by Endo International plc Actient Pharmaceuticals LLC Delaware Indirect Actient Therapeutics, LLC Delaware Indirect Anchen Pharmaceuticals 2, Inc. Delaware Indirect Astora Women’s Health, LLC Delaw